Skip to main content

OCRELIZUMAB

Tracking # 20-819943

$99999.00

There are no ratings for this course

Learn more
CE Broker Reporting Reported automatically
Method Computer-Based Training

Course overview

OCRELIZUMAB IS A MEDICATION USED IN THE MANAGEMENT AND TREATMENT OF PRIMARY PROGRESSIVE AND RELAPSING MULTIPLE SCLEROSIS. IT IS IN THE ANTI-CD20 MONOCLONAL ANTIBODY CLASS OF MEDICATIONS. THIS ACTIVITY DESCRIBES THE INDICATIONS, ACTION, AND CONTRAINDICATIONS FOR OCRELIZUMAB AS A VALUABLE AGENT IN MULTIPLE SCLEROSIS MANAGEMENT. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., ADMINISTRATION, CONTRAINDICATIONS, MONITORING, TOXICITY) PERTINENT FOR MEMBERS OF THE INTERPROFESSIONAL TEAM IN THE CARE OF PATIENTS WITH MULTIPLE SCLEROSIS.

Subject areas

This course counts toward the state boards and subject areas below.

Florida Board of Osteopathic Medicine

Osteopathic Physician

1h General